ArticleFrontiers in immunology2026
Broad and robust T cell immunity compensates the population immune barrier against antibody-escaping Omicron variants.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Continuous SARS-CoV-2 Omicron emergence poses challenges to immune protection from the previous infection/vaccination in the population. While neutralizing antibodies serve as a key immune protection indicator, their cross-protective effect against novel variants remains limited. However, T cell immunity may confer more durable and broad-spectrum protection. Methods: We evaluated immune dynamics in four Chinese cohorts comprising BF.7/BA.5.2, XBB, and JN.1 convalescents, plus tetravalent recombinant protein vaccine recipients. Neutralizing antibodies were assessed against nine variants spanning the emerging evolutionary spectrum. T cell responses were characterized using variant-specific peptide pools. Antigenic relationships were analyzed through multidimensional scaling-based cartography. Results: BF.7/BA.5.2 convalescents exhibited progressive antibody evasion, with fold-changes against heterologous variants increasing from 4-12-fold initially to > 20-fold at 6 months. XBB convalescents maintained stable short-term responses, while JN.1 convalescents showed superior cross-reactivity against descendant lineages. BA.3.2 demonstrated maximal immune evasion across all groups, occupying the most distant antigenic position. In contrast, T cell immunity exhibited remarkable stability and cross-reactivity, maintaining elevated levels at 6 months with balanced responses against all tested variants. The tetravalent vaccine induced broad-spectrum T cell responses comparable to natural infection, and elicited cross-neutralizing antibody responses against different Omicron variants. Discussion: Our study reveals SARS-CoV-2 variant-specific antibody escape compensated by stable cross-reactive T cell responses. In the context of continued viral evolution, stimulating robust T cell immune responses may be critical to achieve a high population immune barrier against future coronaviruses/variants. These findings emphasize the necessity of comprehensive immune evaluation integrating both humoral and cellular components and provide scientific foundations for optimizing vaccine strategies and immune surveillance systems to address emerging viruses and their variants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.